The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.57 — grey zone — between safe and distressedWatch
Where the revenue comes from
Fiscal 2025, as PTC THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Collaboration And License Revenue$1.0B
- Product$586.7M
- Royalty$244.2M
- Translarna1$235.3M
- Emflaza$146.4M
Leadership changes
From PTC THERAPEUTICS, INC.'s own filings, the day they're filed.
- Alethia Young · member of the board of directors · departureeff. 2026-06-08
- Jessica Chutter · directors · appointmenteff. 2026-03-24
- Emily Hill · Chief Financial Officer · departureeff. 2023-08-20
Latest filings
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about PTC THERAPEUTICS, INC., every answer cited🔒
- The Intelligence Brief — added when PTC THERAPEUTICS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.